multivariate regression analysis showed that after controlling for demographics, geographic regions, and comorbidities, the average cost of informal caregivers for the visually impaired was almost four times as high as that of the visually unimpaired.

CONCLUSIONS: Our study indicated that the marginal effect of VI on costs of informal care was higher than many other health problems commonly seen in the elderly, such as diabetes, arthritis, urinary incontinence, etc.

 Abstracts

PES5

COST ANALYSIS OF ISOTRETINOIN FOR SEVERE RECALCITRANT NODULAR ACNE

Neary M1, Peters JC2, Smith MW2, Hong J1, Ellis CN3
1Hoffman La Roche, Nutley, NJ, USA; 2Medstat Group Inc, Washington, DC, USA; 3University of Michigan Medical School, Ann Arbor, MI, USA

OBJECTIVE: Retrospective analysis of administrative claims data was performed to evaluate impact of a single course of isotretinoin therapy on direct cost of medical treatment for severe recalcitrant nodular acne (SRNA). Results were compared with projections of annual cost of conventional therapy (excluding isotretinoin). Data and METHODs: Using the MEDSTAT Marketscan database, we identified 475 subjects aged 12–35 who received a single course of isotretinoin lasting 90 days or longer from 1995–1998. Acne-related expenditures were calculated during isotretinoin treatment and for periods of 12 months pre and post-isotretinoin. Direct costs (isotretinoin, systemic/topical antibiotics, laboratory tests, and doctor office visits) were examined, relative to individual subject characteristics (gender, age, health plan). Applying a published methodology, projections of annual cost of conventional therapy were made by costing an algorithm for treatment, including antibiotic and topical therapies (Bergfeld et al., J Am Acad Dermatol 1995;32 [suppl]:S52–S56).

RESULTS: On average, subjects received isotretinoin for 141 days at cost of $1,231. Mean total acne-related expenses declined from $471 (median, $311) per year prior to isotretinoin therapy to $135 (median, $48) per year after treatment (p < .01). More than 25% of subjects had no acne-related expenditures for at least 12 months post-isotretinoin. Using projections for annual cost of conventional therapies, average total therapy-related expenditure for isotretinoin course ($1543, year 2000 dollars) would be recouped in 8 months for treatment of minocycline + topical tretinoin; with shorter time to recoup cost with branded medications. Projections for combination therapy of topical tretinoin + either oral erythromycin or tetracycline, indicated that isotretinoin expenditure would be recouped in 1.9 to 2.3 years.

CONCLUSION: Isotretinoin therapy substantially reduces total acne-related direct medical expenditures and may result in substantial cost savings. In addition, the comparison of expense for isotretinoin therapy with the estimated annual cost of long-term conventional treatment demonstrates an opportunity for substantial healthcare savings in the treatment of SRNA.

PES6

COST EFFECTIVENESS OF PHOTODYNAMIC THERAPY (PDT) WITH VERTEPORFIN IN THE UK

Smith DH1, Fenn P2, Drummond M3
1Kaiser Permanente Center for Health Research, Portland, OR, USA; 2Nottingham University, Nottingham, UK; 3Innovus Research (UK) Ltd. and University of York, Heslington, York, UK

OBJECTIVES: Age related macular degeneration (AMD) is the leading cause of blindness in the United Kingdom and the rest of the western world, occurring in 15% to 30% of those over 75 years of age. About 15% of these patients develop a more aggressive wet form of the disease that causes severe loss of vision.

METHODs: Costs considered are those for treatment and social care for people with low vision. The benefit estimates come from a 2-year clinical trial of 609 patients that compared PDT with verteporfin to placebo. A Markov model was used to extrapolate the results of the trial to a 5-year time horizon. Transition rates in the model were based on a time-to-event analysis using a Weibull parametric hazard, with the assumption that the treated eye is the better seeing eye. Two outcomes were measured, vision years gained and quality adjusted life years (QALYs) gained.

RESULTS: The cost per vision year gained estimates range from £13,000 to £15,000 over 2 years, while those modeled to 5 years range from £5,000 to £9,000. The cost per QALY gained within the trial time frame range from £58,000 to £66,000, and is estimated to range from £22,000 to £43,000 at 5 years. Earlier intervention has greater expected cost effectiveness in the long term, in spite of more treatments being given overall. For example, with a 5-year follow-up, starting a treatment cohort at 20/40 yields an expected cost per QALY of £22,000–£30,000, while starting a cohort at 20/100 yields an expected cost per QALY of £34,000–£43,000. The main driver in the costs for the treatment group is the cost of therapy, and these costs are estimated to occur mainly in the first 2 years.

CONCLUSION: Early intervention may yield acceptable cost-effectiveness levels. Consideration should be given to early detection and treatment of people with AMD.

Age related macular degeneration (AMD) is the leading cause of blindness in the United Kingdom and the rest of the western world, occurring in 15% to 30% of those over 75 years of age. About 15% of these patients develop a more aggressive wet form of the disease that causes severe loss of vision.